Monopar Therapeutics (MNPR) Competitors

$55.82 -0.44 (-0.77%)

As of 02:19 PM Eastern

MNPR vs. ZYME, PVLA, HRMY, QURE, and NTLA

Should you buy Monopar Therapeutics stock or one of its competitors? MarketBeat compares Monopar Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Monopar Therapeutics include Zymeworks (ZYME), Palvella Therapeutics (PVLA), Harmony Biosciences (HRMY), uniQure (QURE), and Intellia Therapeutics (NTLA). These companies are all part of the "pharmaceutical products" industry.

How does Monopar Therapeutics compare to Zymeworks?

Zymeworks (NASDAQ:ZYME) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

92.9% of Zymeworks shares are owned by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are owned by institutional investors. 33.5% of Zymeworks shares are owned by company insiders. Comparatively, 20.5% of Monopar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Zymeworks currently has a consensus target price of $38.00, suggesting a potential upside of 55.03%. Monopar Therapeutics has a consensus target price of $107.00, suggesting a potential upside of 91.70%. Given Monopar Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Monopar Therapeutics is more favorable than Zymeworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.92
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Monopar Therapeutics has lower revenue, but higher earnings than Zymeworks. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Zymeworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zymeworks	$105.96M	16.89	-$81.13M	-$1.37	N/A
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A

In the previous week, Zymeworks had 1 more articles in the media than Monopar Therapeutics. MarketBeat recorded 14 mentions for Zymeworks and 13 mentions for Monopar Therapeutics. Monopar Therapeutics' average media sentiment score of 1.13 beat Zymeworks' score of 0.57 indicating that Monopar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zymeworks	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Monopar Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Monopar Therapeutics has a net margin of 0.00% compared to Zymeworks' net margin of -126.92%. Monopar Therapeutics' return on equity of -12.84% beat Zymeworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zymeworks	-126.92%	-37.97%	-25.31%
Monopar Therapeutics	N/A	-12.84%	-12.57%

Zymeworks has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, Monopar Therapeutics has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market.

Summary

Monopar Therapeutics beats Zymeworks on 9 of the 15 factors compared between the two stocks.

How does Monopar Therapeutics compare to Palvella Therapeutics?

Palvella Therapeutics (NASDAQ:PVLA) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

Palvella Therapeutics has a beta of -0.13, suggesting that its stock price is 113% less volatile than the broader market. Comparatively, Monopar Therapeutics has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market.

40.1% of Palvella Therapeutics shares are held by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are held by institutional investors. 20.5% of Palvella Therapeutics shares are held by company insiders. Comparatively, 20.5% of Monopar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Monopar Therapeutics had 7 more articles in the media than Palvella Therapeutics. MarketBeat recorded 13 mentions for Monopar Therapeutics and 6 mentions for Palvella Therapeutics. Monopar Therapeutics' average media sentiment score of 1.13 beat Palvella Therapeutics' score of -0.43 indicating that Monopar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palvella Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Monopar Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Monopar Therapeutics' return on equity of -12.84% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palvella Therapeutics	N/A	-56.87%	-42.50%
Monopar Therapeutics	N/A	-12.84%	-12.57%

Palvella Therapeutics currently has a consensus price target of $199.53, suggesting a potential upside of 81.66%. Monopar Therapeutics has a consensus price target of $107.00, suggesting a potential upside of 91.70%. Given Monopar Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Monopar Therapeutics is more favorable than Palvella Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Monopar Therapeutics is trading at a lower price-to-earnings ratio than Palvella Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palvella Therapeutics	N/A	N/A	-$41.72M	-$4.17	N/A
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A

Summary

Monopar Therapeutics beats Palvella Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Monopar Therapeutics compare to Harmony Biosciences?

Monopar Therapeutics (NASDAQ:MNPR) and Harmony Biosciences (NASDAQ:HRMY) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

Harmony Biosciences has a net margin of 16.20% compared to Monopar Therapeutics' net margin of 0.00%. Harmony Biosciences' return on equity of 17.19% beat Monopar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-12.84%	-12.57%
Harmony Biosciences	16.20%	17.19%	11.99%

Monopar Therapeutics has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market. Comparatively, Harmony Biosciences has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

1.8% of Monopar Therapeutics shares are held by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are held by institutional investors. 20.5% of Monopar Therapeutics shares are held by insiders. Comparatively, 11.0% of Harmony Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Monopar Therapeutics currently has a consensus target price of $107.00, indicating a potential upside of 91.70%. Harmony Biosciences has a consensus target price of $40.89, indicating a potential upside of 35.43%. Given Monopar Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Monopar Therapeutics is more favorable than Harmony Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Harmony Biosciences	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27

Harmony Biosciences has higher revenue and earnings than Monopar Therapeutics. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A
Harmony Biosciences	$868.45M	2.01	$158.69M	$2.48	12.17

In the previous week, Monopar Therapeutics had 9 more articles in the media than Harmony Biosciences. MarketBeat recorded 13 mentions for Monopar Therapeutics and 4 mentions for Harmony Biosciences. Monopar Therapeutics' average media sentiment score of 1.13 beat Harmony Biosciences' score of 0.74 indicating that Monopar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monopar Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Harmony Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Monopar Therapeutics and Harmony Biosciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Monopar Therapeutics compare to uniQure?

uniQure (NASDAQ:QURE) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, media sentiment, dividends, profitability and analyst recommendations.

78.8% of uniQure shares are held by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are held by institutional investors. 4.8% of uniQure shares are held by insiders. Comparatively, 20.5% of Monopar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

uniQure has a beta of 0.87, meaning that its share price is 13% less volatile than the broader market. Comparatively, Monopar Therapeutics has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market.

Monopar Therapeutics has lower revenue, but higher earnings than uniQure. Monopar Therapeutics is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$16.10M	98.24	-$198.97M	-$3.48	N/A
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A

In the previous week, Monopar Therapeutics had 9 more articles in the media than uniQure. MarketBeat recorded 13 mentions for Monopar Therapeutics and 4 mentions for uniQure. Monopar Therapeutics' average media sentiment score of 1.13 beat uniQure's score of 0.90 indicating that Monopar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
uniQure	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Monopar Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Monopar Therapeutics has a net margin of 0.00% compared to uniQure's net margin of -1,154.42%. Monopar Therapeutics' return on equity of -12.84% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-1,154.42%	-145.81%	-27.15%
Monopar Therapeutics	N/A	-12.84%	-12.57%

uniQure currently has a consensus price target of $42.83, indicating a potential upside of 70.80%. Monopar Therapeutics has a consensus price target of $107.00, indicating a potential upside of 91.70%. Given Monopar Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Monopar Therapeutics is more favorable than uniQure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.53
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Monopar Therapeutics beats uniQure on 12 of the 15 factors compared between the two stocks.

How does Monopar Therapeutics compare to Intellia Therapeutics?

Monopar Therapeutics (NASDAQ:MNPR) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.

In the previous week, Intellia Therapeutics had 10 more articles in the media than Monopar Therapeutics. MarketBeat recorded 23 mentions for Intellia Therapeutics and 13 mentions for Monopar Therapeutics. Monopar Therapeutics' average media sentiment score of 1.13 beat Intellia Therapeutics' score of 0.32 indicating that Monopar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monopar Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Intellia Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Monopar Therapeutics has a net margin of 0.00% compared to Intellia Therapeutics' net margin of -597.04%. Monopar Therapeutics' return on equity of -12.84% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-12.84%	-12.57%
Intellia Therapeutics	-597.04%	-57.47%	-46.24%

1.8% of Monopar Therapeutics shares are held by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are held by institutional investors. 20.5% of Monopar Therapeutics shares are held by insiders. Comparatively, 3.1% of Intellia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Monopar Therapeutics has higher earnings, but lower revenue than Intellia Therapeutics. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A
Intellia Therapeutics	$67.67M	25.18	-$412.69M	-$3.54	N/A

Monopar Therapeutics has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.93, indicating that its share price is 93% more volatile than the broader market.

Monopar Therapeutics currently has a consensus price target of $107.00, suggesting a potential upside of 91.70%. Intellia Therapeutics has a consensus price target of $20.25, suggesting a potential upside of 66.05%. Given Monopar Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Monopar Therapeutics is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Intellia Therapeutics	3 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.35

Summary

Monopar Therapeutics beats Intellia Therapeutics on 11 of the 16 factors compared between the two stocks.

Get Monopar Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MNPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MNPR vs. The Competition

Export

Metric	Monopar Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$373.96M	$3.27B	$6.29B	$12.15B
Dividend Yield	N/A	2.33%	2.80%	5.32%
P/E Ratio	-29.38	18.74	20.64	25.14
Price / Sales	N/A	281.73	580.02	91.94
Price / Cash	N/A	55.27	27.48	37.30
Price / Book	2.71	6.61	9.75	6.65
Net Income	-$13.72M	$24.30M	$3.55B	$335.51M
7 Day Performance	-9.02%	-3.01%	-1.59%	-1.56%
1 Month Performance	-0.72%	-7.31%	-3.51%	-1.44%
1 Year Performance	51.26%	53.03%	30.08%	28.08%

Monopar Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MNPR Monopar Therapeutics	2.5494 of 5 stars	$55.82 -0.8%	$107.00 +91.7%	+51.4%	$373.96M	N/A	N/A	10	Positive News Earnings Report Analyst Revision
ZYME Zymeworks	3.2796 of 5 stars	$23.90 -0.5%	$38.00 +59.0%	N/A	$1.75B	$105.96M	N/A	460	Buyback Announcement
PVLA Palvella Therapeutics	3.1239 of 5 stars	$125.79 +3.0%	$199.53 +58.6%	+376.4%	$1.75B	$42.81M	N/A	N/A
HRMY Harmony Biosciences	4.7604 of 5 stars	$30.15 -0.1%	$40.89 +35.6%	-14.9%	$1.75B	$868.45M	12.17	200
QURE uniQure	3.4015 of 5 stars	$29.10 +5.3%	$42.83 +47.2%	+82.0%	$1.74B	$16.10M	N/A	500	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MNPR) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Monopar Therapeutics (MNPR) Competitors

MNPR vs. ZYME, PVLA, HRMY, QURE, and NTLA

How does Monopar Therapeutics compare to Zymeworks?

Summary

How does Monopar Therapeutics compare to Palvella Therapeutics?

Summary

How does Monopar Therapeutics compare to Harmony Biosciences?

Summary

How does Monopar Therapeutics compare to uniQure?

Summary

How does Monopar Therapeutics compare to Intellia Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNPR vs. The Competition

Monopar Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Monopar Therapeutics (MNPR) Competitors

MNPR vs. ZYME, PVLA, HRMY, QURE, and NTLA

How does Monopar Therapeutics compare to Zymeworks?

Do institutionals & insiders hold more shares of ZYME or MNPR?

Do analysts rate ZYME or MNPR?

Which has higher earnings and valuation, ZYME or MNPR?

Does the media prefer ZYME or MNPR?

Is ZYME or MNPR more profitable?

Which has more risk and volatility, ZYME or MNPR?

Summary

How does Monopar Therapeutics compare to Palvella Therapeutics?

Which has more volatility & risk, PVLA or MNPR?

Do insiders & institutionals hold more shares of PVLA or MNPR?

Does the media favor PVLA or MNPR?

Is PVLA or MNPR more profitable?

Do analysts prefer PVLA or MNPR?

Which has stronger earnings and valuation, PVLA or MNPR?

Summary

How does Monopar Therapeutics compare to Harmony Biosciences?

Is MNPR or HRMY more profitable?

Which has more risk & volatility, MNPR or HRMY?

Do insiders and institutionals believe in MNPR or HRMY?

Do analysts rate MNPR or HRMY?

Which has higher valuation & earnings, MNPR or HRMY?

Does the media refer more to MNPR or HRMY?

Summary

How does Monopar Therapeutics compare to uniQure?

Do institutionals & insiders have more ownership in QURE or MNPR?

Which has more volatility & risk, QURE or MNPR?

Which has better valuation and earnings, QURE or MNPR?

Does the media favor QURE or MNPR?

Is QURE or MNPR more profitable?

Do analysts rate QURE or MNPR?

Summary

How does Monopar Therapeutics compare to Intellia Therapeutics?

Does the media refer more to MNPR or NTLA?

Is MNPR or NTLA more profitable?

Do insiders & institutionals have more ownership in MNPR or NTLA?

Which has preferable valuation & earnings, MNPR or NTLA?

Which has more risk and volatility, MNPR or NTLA?

Do analysts recommend MNPR or NTLA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNPR vs. The Competition

Monopar Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools